Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.

Advertisement

Related Content

Reinvigorated Antibiotics Pipeline Could Produce Four NMEs In 2014
CROs Getting Govt. Support To Help Countermeasure Sponsors
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics
Mirror, Mirror: Long-acting Antibiotics Dalbavancin, Oritavancin Emerging With Similar Profiles
BARDA To Fund Pediatric Development Of Cempra’s Solithromycin
Financial Incentives Seen As A Path To Resurgence Of Antibiotics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel